Full history for every metric is available with a Kvantra account
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 934 | 1,064 | 1,216 | 1,247 | 1,397 | 1,465 | 1,494 | 1,551 |
| Operating profit | €m | 217 | 219 | ||||||
| Net profit | €m | 136 | 113 | 122 | 121 | 145 | 151 | 156 | 176 |
| EPS reported | € | 17.98 | 18.55 | ||||||
| Operating cashflow per share | € | 23.32 | 26.36 | ||||||
| Capex per share | € | 10.99 | 11.24 | ||||||
| FCF per share | € | 12.32 | 15.12 | ||||||
| Free cash flow | €m | 103 | 127 | ||||||
| Net debt | €m | 127 | 188 | ||||||
| Book value equity | €m | 1,125 | 1,217 | ||||||
| Book value per share | € | 134.1 | 145.1 | ||||||
| Number of shares | m | 8.39 | 8.39 | ||||||
| DPS (TTM paid) | € | 1.45 | 1.45 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 19.88 | - | ||||||
| P/B LTM | x | 2.67 | 2.12 | ||||||
| P/S LTM | x | 2.05 | 1.73 | ||||||
| P/FCF LTM | x | 29.01 | 20.37 | ||||||
| EV/EBITDA LTM | x | 11.39 | 9.60 | ||||||
| EV/Sales LTM | x | 2.16 | 1.85 | ||||||
| Earnings Yield LTM | % | 5.03% | 6.04% | ||||||
| FCF Yield | % | 3.45% | 4.91% | ||||||
| Quality | |||||||||
| ROE | % | 13.41% | 13.31% | ||||||
| ROIC | % | 10.53% | 8.98% | ||||||
| Operating margin | % | 14.80% | 14.67% | ||||||
| Gross margin | % | 35.36% | 20.15% | ||||||
| FCF/Sales | % | 7.06% | 8.48% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +3.69% | +16.81% | ||||||
| Sales Growth YoY | % | +4.82% | +4.30% | ||||||
| Net Income Growth YoY | % | +3.85% | +17.15% | ||||||
| FCF Growth | % | -23.39% | +30.72% | ||||||
| Operating Profit Growth | % | -0.13% | +6.65% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.40% | 0.46% | ||||||
| Dividend Growth | % | - | 0.00% | ||||||
| Payout Ratio | % | 8.05% | 8.05% | ||||||
| FCF/Debt | x | 0.36 | 0.35 | ||||||
| Net Debt/EBITDA | x | 0.60 | 0.65 | ||||||
| EBIT/Net interest | x | 24.54 | 22.84 | ||||||
| Net debt/market cap | % | 4.25% | 7.30% | ||||||
| Net debt/Equity | x | 0.11 | 0.15 | ||||||
| Gross debt/equity | x | 0.26 | 0.30 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Founded in 1968 and based in Carros, France, Virbac S.A. is a prominent developer and distributor of a wide array of animal health products and services. The company's global operations extend across France, Europe, Latin America, North America, Asia Pacific, the Middle East, and Africa, catering to both domestic companion animals and commercial livestock. Its extensive portfolio encompasses vaccines, dental hygiene products, reproductive health solutions, dermatological treatments, parasiticides, diagnostic instruments, antibiotics, and aquaculture offerings. Furthermore, Virbac supplies specialized veterinary pharmaceuticals for anesthesia, geriatric care, behavioral management, and injectable micronutrients, alongside pet food and electronic identification systems. These diverse solutions are designed to support veterinarians, agricultural producers, and individual pet owners worldwide.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Based on consensus from external analysts. Not Kvantra's opinion.
Founded in 1968 and based in Carros, France, Virbac S.A. is a prominent developer and distributor of a wide array of animal health products and services. The company's global operations extend across France, Europe, Latin America, North America, Asia Pacific, the Middle East, and Africa, catering to both domestic companion animals and commercial livestock. Its extensive portfolio encompasses vaccines, dental hygiene products, reproductive health solutions, dermatological treatments, parasiticides, diagnostic instruments, antibiotics, and aquaculture offerings. Furthermore, Virbac supplies specialized veterinary pharmaceuticals for anesthesia, geriatric care, behavioral management, and injectable micronutrients, alongside pet food and electronic identification systems. These diverse solutions are designed to support veterinarians, agricultural producers, and individual pet owners worldwide.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free